CN102573462B - 用于降低尿酸的3位取代的化合物 - Google Patents

用于降低尿酸的3位取代的化合物 Download PDF

Info

Publication number
CN102573462B
CN102573462B CN201080046070.0A CN201080046070A CN102573462B CN 102573462 B CN102573462 B CN 102573462B CN 201080046070 A CN201080046070 A CN 201080046070A CN 102573462 B CN102573462 B CN 102573462B
Authority
CN
China
Prior art keywords
formula
compound
reaction
hydrogen
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080046070.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102573462A (zh
Inventor
沙林·夏尔马
詹姆斯·邓恩·奥尼尔
里德·W·冯博斯特尔
拉姆钱德兰·阿鲁德钱德兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Therapeutics Corp
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of CN102573462A publication Critical patent/CN102573462A/zh
Application granted granted Critical
Publication of CN102573462B publication Critical patent/CN102573462B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01G—CAPACITORS; CAPACITORS, RECTIFIERS, DETECTORS, SWITCHING DEVICES, LIGHT-SENSITIVE OR TEMPERATURE-SENSITIVE DEVICES OF THE ELECTROLYTIC TYPE
    • H01G9/00—Electrolytic capacitors, rectifiers, detectors, switching devices, light-sensitive or temperature-sensitive devices; Processes of their manufacture
    • H01G9/0029—Processes of manufacture
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01G—CAPACITORS; CAPACITORS, RECTIFIERS, DETECTORS, SWITCHING DEVICES, LIGHT-SENSITIVE OR TEMPERATURE-SENSITIVE DEVICES OF THE ELECTROLYTIC TYPE
    • H01G9/00—Electrolytic capacitors, rectifiers, detectors, switching devices, light-sensitive or temperature-sensitive devices; Processes of their manufacture
    • H01G9/004—Details
    • H01G9/022—Electrolytes; Absorbents
    • H01G9/025—Solid electrolytes
    • H01G9/028—Organic semiconducting electrolytes, e.g. TCNQ
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01G—CAPACITORS; CAPACITORS, RECTIFIERS, DETECTORS, SWITCHING DEVICES, LIGHT-SENSITIVE OR TEMPERATURE-SENSITIVE DEVICES OF THE ELECTROLYTIC TYPE
    • H01G9/00—Electrolytic capacitors, rectifiers, detectors, switching devices, light-sensitive or temperature-sensitive devices; Processes of their manufacture
    • H01G9/15—Solid electrolytic capacitors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Power Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Electrochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Manufacturing & Machinery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Laminated Bodies (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
CN201080046070.0A 2009-10-13 2010-10-07 用于降低尿酸的3位取代的化合物 Expired - Fee Related CN102573462B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25109809P 2009-10-13 2009-10-13
US61/251,098 2009-10-13
PCT/US2010/051781 WO2011046800A1 (en) 2009-10-13 2010-10-07 3-substituted compounds for reducing uric acid

Publications (2)

Publication Number Publication Date
CN102573462A CN102573462A (zh) 2012-07-11
CN102573462B true CN102573462B (zh) 2014-04-16

Family

ID=43876448

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080046070.0A Expired - Fee Related CN102573462B (zh) 2009-10-13 2010-10-07 用于降低尿酸的3位取代的化合物

Country Status (5)

Country Link
US (1) US8546448B2 (enExample)
EP (1) EP2488020B1 (enExample)
JP (1) JP5806221B2 (enExample)
CN (1) CN102573462B (enExample)
WO (1) WO2011046800A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012033720A1 (en) 2010-09-08 2012-03-15 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
US8808403B2 (en) * 2010-09-15 2014-08-19 Kemet Electronics Corporation Process for solid electrolytic capacitors using polymer slurries
EP2998296B1 (en) 2013-05-13 2018-03-14 Shanghai Hengrui Pharmaceutical Co. Ltd. Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
CN104230833B (zh) * 2014-10-07 2016-01-20 张远强 含腈基的四氮唑乙酸类化合物、其制备方法及用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024253A (en) * 1973-04-20 1977-05-17 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Treatment of elevated histamine and uric acid levels
US20040019208A1 (en) * 2002-07-18 2004-01-29 Alex Nivorozhkin 5-Aryltetrazole Compounds, compositions thereof, and uses therefor
US20080015254A1 (en) * 2003-02-13 2008-01-17 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US20080015209A1 (en) * 2001-06-12 2008-01-17 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1482195A (en) * 1973-08-23 1977-08-10 Beecham Group Ltd Biologically active phenyl(thio)ether derivatives
US5274000A (en) * 1982-10-19 1993-12-28 Kotobuki Seiyaku Company Limited Benzofuran and benzothiophene derivatives, anti-hyperuricemia agents
FR2631827B1 (fr) * 1988-05-27 1992-03-27 Delalande Sa Nouveaux derives d'(hetero)aryl-5 tetrazole, leur procede de preparation et leur application en therapeutique
US5064830A (en) * 1990-08-02 1991-11-12 Pfizer Inc. Lowering of blood uric acid levels
US7419980B2 (en) * 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
EP1841749A1 (en) * 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
US20060211697A1 (en) * 2004-12-08 2006-09-21 Liren Huang 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents
EP1849465A4 (en) * 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
WO2008066131A1 (en) * 2006-12-01 2008-06-05 Banyu Pharmaceutical Co., Ltd. Novel phenyl-isoxazol-3-ol derivative
BRPI0808196A2 (pt) * 2007-03-08 2014-07-08 Plexxikon Inc Compostos ativos de ppar
CN101969773B (zh) * 2008-03-13 2015-08-19 维尔斯达医疗公司 用于降低尿酸的化合物和方法
ES2561039T3 (es) * 2008-04-30 2016-02-24 Wellstat Therapeutics Corporation Compuestos tetrazol para reducir el ácido úrico
GB0810617D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical
GB0810615D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024253A (en) * 1973-04-20 1977-05-17 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Treatment of elevated histamine and uric acid levels
US20080015209A1 (en) * 2001-06-12 2008-01-17 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US20040019208A1 (en) * 2002-07-18 2004-01-29 Alex Nivorozhkin 5-Aryltetrazole Compounds, compositions thereof, and uses therefor
US20080015254A1 (en) * 2003-02-13 2008-01-17 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Also Published As

Publication number Publication date
EP2488020A1 (en) 2012-08-22
EP2488020B1 (en) 2016-12-14
JP2013507438A (ja) 2013-03-04
JP5806221B2 (ja) 2015-11-10
EP2488020A4 (en) 2013-04-10
CN102573462A (zh) 2012-07-11
US8546448B2 (en) 2013-10-01
US20120201803A1 (en) 2012-08-09
WO2011046800A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
EP3302471B1 (en) Tetrasubstituted alkene compounds and their use
Gardinier et al. Enforced Helicity: Efficient Access to Self‐Organized Helical Molecular Strands by the Imine Route
CN102976928B (zh) 用于降低尿酸的化合物
TWI471325B (zh) Indole (Indolizine) derivatives and their pharmaceutical use
JP7090770B2 (ja) Ｅｐ４アンタゴニスト
TWI675026B (zh) 稠環衍生物、其製備方法、中間體、藥物組合物及應用
CN102573462B (zh) 用于降低尿酸的3位取代的化合物
BRPI0411613B1 (pt) sal de 3-benzazepinas
WO2007091570A1 (ja) スフィンゴシン－１－リン酸結合阻害物質
CA2468071A1 (fr) Derives de triazolo[4,3-a]pyrido[2,3-d]pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
CN103265420A (zh) 一种芳香二酮化合物的制备方法
CN102203085A (zh) 用于制备苹果酸舒尼替尼晶体形式的新方法
TW200811083A (en) 2-aminobutanol compounds and their medical use
JPS63132876A (ja) 置換１ｈ−イミダゾール化合物
WO2012125533A1 (en) 3-benzyloxyphenyloxoacetic acid compounds for reducing uric acid
JP2020531522A (ja) Ｐａｒｐ−１阻害剤の結晶形態およびその製造方法
CN113896683A (zh) 一种帕唑帕尼关键中间体的制备方法
CN108218798A (zh) Apabetalone的制备方法
CN103608337B (zh) Pet放射性医疗用品的18f-标记前体及其制备方法
JP7716980B2 (ja) エストロゲン受容体拮抗剤
CN102050796B (zh) α,α,α',α'-四甲基-5-(1氢-1,3,4-三氮唑-1-基甲基)-1,3-苯二乙腈的制备方法
CN103396346A (zh) 光学活性氨基醇衍生物的制备方法
EP3677581A1 (en) Deuterated indoleamine 2,3-dioxygenase inhibitor and application thereof
CN114835688B (zh) 一种取代的4-芳基咪唑-2-酮衍生物及其制备方法和医药用途
RS58539B1 (sr) Nova jedinjenja kao inhibitori diacilglicerin aciltransferaze

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140416

Termination date: 20141007

EXPY Termination of patent right or utility model